October 29, 2021 -- BridgeBio Pharma announced it is collaborating with Columbia University and Mount Sinai Health System to develop potential therapies to treat individuals with genetic diseases and cancers.
The company has initiated 25 collaborations with leading institutions around the world that are focused on providing therapeutic options to patients with unmet needs.
BridgeBio noted Columbia University and Mount Sinai's respective expertise in developing breakthroughs for patients with genetic diseases and genetically driven cancers.